These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23990173)

  • 41. Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.
    Manrique SZ; Dominguez AL; Mirza N; Spencer CD; Bradley JM; Finke JH; Lee JJ; Pease LR; Gendler SJ; Cohen PA
    Oncotarget; 2016 Jul; 7(28):42919-42942. PubMed ID: 27341020
    [TBL] [Abstract][Full Text] [Related]  

  • 42. T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy.
    Raber PL; Sierra RA; Thevenot PT; Shuzhong Z; Wyczechowska DD; Kumai T; Celis E; Rodriguez PC
    Oncotarget; 2016 Apr; 7(14):17565-78. PubMed ID: 27007050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.
    Krishnamoorthy M; Gerhardt L; Maleki Vareki S
    Cells; 2021 May; 10(5):. PubMed ID: 34065010
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas.
    Hamilton MJ; Bosiljcic M; Lepard NE; Halvorsen EC; Ho VW; Banáth JP; Krystal G; Bennewith KL
    J Immunol; 2014 Jan; 192(1):512-22. PubMed ID: 24285836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
    Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
    J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.
    Rodríguez PC; Ochoa AC
    Immunol Rev; 2008 Apr; 222():180-91. PubMed ID: 18364002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
    Bazargan S; Bunch B; Ojwang' AME; Blauvelt J; Landin A; Ali J; Abrahams D; Cox C; Hall AM; Beatty MS; Poch M; Rejniak KA; Pilon-Thomas S
    Front Immunol; 2023; 14():1275375. PubMed ID: 37901214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
    Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
    J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure.
    Zhou L; Miao K; Yin B; Li H; Fan J; Zhu Y; Ba H; Zhang Z; Chen F; Wang J; Zhao C; Li Z; Wang DW
    Circulation; 2018 Jul; 138(2):181-197. PubMed ID: 29437117
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deletion of Rac1GTPase in the Myeloid Lineage Protects against Inflammation-Mediated Kidney Injury in Mice.
    Nagase M; Kurihara H; Aiba A; Young MJ; Sakai T
    PLoS One; 2016; 11(3):e0150886. PubMed ID: 26939003
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of tumors with vitamin E suppresses myeloid derived suppressor cells and enhances CD8+ T cell-mediated antitumor effects.
    Kang TH; Knoff J; Yeh WH; Yang B; Wang C; Kim YS; Kim TW; Wu TC; Hung CF
    PLoS One; 2014; 9(7):e103562. PubMed ID: 25072795
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myeloid-derived suppressor cells limit the inflammation by promoting T lymphocyte apoptosis in the spinal cord of a murine model of multiple sclerosis.
    Moliné-Velázquez V; Cuervo H; Vila-Del Sol V; Ortega MC; Clemente D; de Castro F
    Brain Pathol; 2011 Nov; 21(6):678-91. PubMed ID: 21507122
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
    Park JA; Wang L; Cheung NV
    J Hematol Oncol; 2021 Sep; 14(1):142. PubMed ID: 34496935
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
    Srivastava MK; Zhu L; Harris-White M; Kar UK; Huang M; Johnson MF; Lee JM; Elashoff D; Strieter R; Dubinett S; Sharma S
    PLoS One; 2012; 7(7):e40677. PubMed ID: 22815789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.
    Kodumudi KN; Woan K; Gilvary DL; Sahakian E; Wei S; Djeu JY
    Clin Cancer Res; 2010 Sep; 16(18):4583-94. PubMed ID: 20702612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The adaptor protein TRAF3 is an immune checkpoint that inhibits myeloid-derived suppressor cell expansion.
    Zhu S; Lalani AI; Jin J; Sant'Angelo D; Covey LR; Liu K; Young HA; Ostrand-Rosenberg S; Xie P
    Front Immunol; 2023; 14():1167924. PubMed ID: 37207205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
    Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
    Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of PPARγ in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis.
    Wu L; Yan C; Czader M; Foreman O; Blum JS; Kapur R; Du H
    Blood; 2012 Jan; 119(1):115-26. PubMed ID: 22053106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines.
    Chen HW; Chen HY; Wang LT; Wang FH; Fang LW; Lai HY; Chen HH; Lu J; Hung MS; Cheng Y; Chen MY; Liu SJ; Chong P; Lee OK; Hsu SC
    J Immunol; 2013 May; 190(10):5065-77. PubMed ID: 23589610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer.
    Hu X; Bardhan K; Paschall AV; Yang D; Waller JL; Park MA; Nayak-Kapoor A; Samuel TA; Abrams SI; Liu K
    J Biol Chem; 2013 Jun; 288(26):19103-15. PubMed ID: 23677993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.